Epidemiology and prevention of neonatal candidiasis: Fluconazole for all neonates?

Advances in Experimental Medicine and Biology

Volumn 659, Issue , 2010, Pages 99-119

  Kaufman, David A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; NYSTATIN; PLACEBO;

ANTIFUNGAL RESISTANCE; ARTICLE; BACTERIAL INFECTION; BIOFILM; BLOODSTREAM INFECTION; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDIASIS; CHOLESTASIS; COST BENEFIT ANALYSIS; DEVELOPMENTAL DISORDER; DOSAGE SCHEDULE COMPARISON; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; FUNGAL COLONIZATION; HIGH RISK PATIENT; HOSPITALIZATION COST; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INFECTION RATE; INVASIVE CANDIDIASIS; LIVER FUNCTION; MENINGITIS; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN INTENSIVE CARE; NEWBORN MORTALITY; PREMATURITY; PRIORITY JOURNAL; PROGNOSIS; RESUSCITATION; RISK FACTOR; SIDE EFFECT; URINARY TRACT INFECTION; ANIMAL; CANDIDA; DRUG EFFECT; MICROBIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW;

CANDIDA;

ANIMALS; CANDIDA; CANDIDIASIS; FLUCONAZOLE; HUMANS; INFANT, NEWBORN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 77950348940     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0981-7_9     Document Type: Article

References (77)

1. Aghai, Z.H., Mudduluru, M., Nakhla, T.A., Amendolia, B., Longo, D., Kemble, N., Kaki, S., Sutsko, R., Saslow, J.G., & Stahl, G.E. (2006). Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol, (26), 550-555. (Pubitemid 44305065)
2. Benjamin, D.K., DeLong, E., Cotten, C.M., Garges, H.P., Steinbach, W.J., & Clark, R.H. (2004). Mortality following blood culture in premature infants: increased with gram-negative bacteremia and candidemia, but not gram-positive bacteremia. J Perinatol, (24), 175-180. (Pubitemid 38515157)
3. Benjamin, D.K., Jr., DeLong, E.R., Steinbach, W.J., Cotton, C.M., Walsh, T.J., & Clark, R.H. (2003). Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics, (112), 543-547. (Pubitemid 37082104)
4. Benjamin, D.K., Jr., Stoll, B.J., Fanaroff, A.A., McDonald, S.A., Oh, W., Higgins, R.D., Duara, S., Poole, K., Laptook, A., & Goldberg, R. (2006). Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics, 117(1), 84-92. (Pubitemid 46050523)
5. Bertini, G., Perugi, S., Dani, C., Filippi, L., Pratesi, S., & Rubaltelli, F.F. (2005). Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr, (147), 162-165. (Pubitemid 41207827)
6. Burwell, L.A., Kaufman, D., Blakely, J., Stoll, B.J., & Fridkin, S.K. (2006). Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. Pediatrics, (118), e1019-e1026. (Pubitemid 46393750)
7. Clancy, C.J., Staley, B., & Nguyen, M.H. (2006). In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob Agents Chemother, (50), 3496-3498. (Pubitemid 44527536)
8. Clerihew, L., Austin, N., & McGuire, W. (2007). Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev, CD003850.
9. Clerihew, L., Lamagni, T.L., Brocklehurst, P., & McGuire, W. (2006). Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed, (91), F188-F192. (Pubitemid 43667617)
10. Clerihew, L. &McGuire,W. (2007). Antifungal prophylaxis for very-low-birth-weight infants: UK national survey. Arch Dis Child Fetal Neonatal Ed, 93(3), F238-F239.
11. Cotten, C.M., McDonald, S., Stoll, B., Goldberg, R.N., Poole, K., & BenjaminJr., D.K. (2006). The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics, (118), 717-722.
12. El Masry, F.A., Neal, T.J., & Subhedar, N.V. (2002). Risk factors for invasive fungal infection in neonates. Acta Paediatr, (91), 198-202. (Pubitemid 34252529)
13. Ellepola, A.N. & Samaranayake, L.P. (1998). Adhesion of oral C. albicans to human buccal epithelial cells following limited exposure to antifungal agents. J Oral Pathol Med, (27), 325-332. (Pubitemid 28382639)
14. Faergemann, J. & Laufen, H. (1993). Levels of fluconazole in serum, stratum corneum, epidermisdermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol, (18), 102-106. (Pubitemid 23098392)
15. Fairchild, K.D., Tomkoria, S., Sharp, E.C., & Mena, F.V. (2002). Neonatal Candida glabrata sepsis: clinical and laboratory features compared with other Candida species. Pediatr Infect Dis J, (21), 39-43. (Pubitemid 34073957)
16. Feja, K.N.,Wu, F., Roberts, K., Loughrey,M., Nesin, M., Larson, E., la-Latta, P., Haas, J., Cimiotti, J., & Saiman, L. (2005). Risk factors for candidemia in critically Ill infants: a matched casecontrol study. J Pediatr, (147), 156-161. (Pubitemid 41207826)
17. Fridkin, S.K., Kaufman, D., Edwards, J.R., Shetty, S., & Horan, T. (2006). Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics, (117), 1680-1687. (Pubitemid 46071397)
18. Ghannoum, M.A., Filler, S.G., Ibrahim, A.S., Fu, Y., & Edwards, J.E., Jr. (1992). Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B. Antimicrob Agents Chemother, (36), 2239-2244.
19. Guillet, R., Stoll, B.J., Cotten, C.M., Gantz,M., McDonald, S., Poole,W.K., &Phelps, D.L. (2006). Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics, (117), e137-e142. (Pubitemid 46071566)
20. Hack, M. (2006). Neonatology fellowship training in research pertaining to development and follow-up. J Perinatol, 26(Suppl 2), S30-S33. (Pubitemid 43970940)
21. Hazen, K.C., Coleman, E., & Wu, G. (2000). Influence of fluconazole at subinhibitory concentrations on cell surface hydrophobicity and phagocytosis of Candida albicans. FEMS Microbiol Lett, (183), 89-94. (Pubitemid 30067728)
22. Healy, C.M., Baker, C.J., Zaccaria, E., & Campbell, J.R. (2005). Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr, (147), 166-171. (Pubitemid 41207828)
23. Healy, C.M., Campbell, J.R., Zaccaria, E., & Baker, C.J. (2008). Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics, (121), 703-710.
24. Hof, H. (2008). Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist Updat, 11(1-2), 25-31.
25. Houang, E.T., Chappatte, O., Byrne, D., Macrae, P.V., & Thorpe, J.E. (1990). Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother, (34), 909-910. (Pubitemid 20142425)
26. Hylander, M.A., Strobino, D.M., & Dhanireddy, R. (1998). Human milk feedings and infection among very low birth weight infants. Pediatrics, (102), E38.
27. Johnson, D.E., Thompson, T.R., Green, T.P., & Ferrieri, P. (1984). Systemic candidiasis in very low-birth-weight infants (less than 1,500 grams). Pediatrics, (73), 138-143. (Pubitemid 14188493)
28. Johnsson, H. & Ewald, U. (2004). The rate of candidaemia in preterm infants born at a gestational age of 23-28 weeks is inversely correlated to gestational age. Acta Paediatr, (93), 954-958. (Pubitemid 38829841)
29. Kaufman, D.A. (2008a). Prevention of invasive Candida infections in preterm infants: the time is now. Expert Rev Anti Infect Ther, (6), 393-399.
30. Kaufman, D. (2008b). Fluconazole prophylaxis decreases the combined outcome of invasive Candida infections or mortality in preterm infants. Pediatrics, (122), 1158-1159.
31. Kaufman, D.A. (2008c). Fluconazole prophylaxis: can we eliminate invasive Candida infections in the neonatal ICU? Curr Opin Pediatr, 20(3), 332-340. (Pubitemid 351670540)
32. Kaufman, D., Boyle, R., Hazen, K.C., Patrie, J.T., Robinson, M., & Donowitz, L.G. (2001). Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med, (345), 1660-1666. (Pubitemid 33126821)
33. Kaufman, D., Boyle, R., Hazen, K.C., Patrie, J.T., Robinson, M., & Grossman, L.B. (2005). Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr, (147), 172-179. (Pubitemid 41207829)
34. Kaufman, D., Boyle, R., Robinson, M., & Grossman, L.B. (2003). Long-term safety of intravenous prophylactic fluconazole use in preterm infants less than 1000 grams. Pediatr Res, (53), 484A. Ref Type: Abstract.
35. Kaufman, D.A., Gurka, M.J., Hazen, K.C., Boyle, R., Robinson, M., & Grossman, L.B. (2006). Patterns of fungal colonization in preterm infants weighing less than 1000 grams at birth. Pediatr Infect Dis J, (25), 733-737. (Pubitemid 44162132)
36. Kaufman, D.A., Manzoni, P., Gurka, M.J., & Grossman, L.B. (2007). Antifungal Prophylaxis in the Neonatal Intensive Care Unit (NICU). Curr Pediatr Rev, 277-288. (Pubitemid 350130944)
37. Kicklighter, S.D., Springer, S.C., Cox, T., Hulsey, T.C., & Turner, R.B. (2001). Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics, (107), 293-298. (Pubitemid 32121244)
38. Kojic, E.M. & Darouiche, R.O. (2004). Candida infections of medical devices. Clin Microbiol Rev, (17), 255-267. (Pubitemid 38534029)
39. Koks, C.H., Crommentuyn, K.M., Hoetelmans, R.M., Mathot, R.A., & Beijnen, J.H. (2001). Can fluconazole concentrations in saliva be used for therapeutic drug monitoring? Ther Drug Monit, (23), 449-453. (Pubitemid 32708934)
40. Kramer, M.S., Platt, R.W., Wen, S.W., Joseph, K.S., Allen, A., Abrahamowicz, M., Blondel, B., & Breart, G. (2001). A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics, (108), E35.
41. Leibovitz, E., Iuster-Reicher, A., Amitai, M., & Mogilner, B. (1992). Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin Infect Dis, (14), 485-491.
42. Makhoul, I.R., Bental, Y., Weisbrod, M., Sujov, P., Lusky, A., & Reichman, B. (2007). Candidal versus bacterial late-onset sepsis in very low birthweight infants in Israel: a national survey. J Hosp Infect, (65), 237-243.
43. Makhoul, I.R., Sujov, P., Smolkin, T., Lusky, A., & Reichman, B. (2002). Epidemiological, clinical, and microbiological characteristics of late- onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics, (109), 34-39. (Pubitemid 34049424)
44. Makhoul, I.R., Sujov, P., Smolkin, T., Lusky, A., & Reichman, B. (2005). Pathogen-specific early mortality in very low birth weight infants with late-onset sepsis: a national survey. Clin Infect Dis, (40), 218-224. (Pubitemid 40110664)
45. Manzoni, P., Arisio, R., Mostert, M., Leonessa, M., Farina, D., Latino, M.A., & Gomirato, G. (2006a). Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics, (117), e22-e32. (Pubitemid 46050500)
46. Manzoni, P., Farina, D., Antonielli, D.E., Leonessa, M.L., Gomirato, G., & Arisio, R. (2006b). An association between anatomic site of Candida colonization and risk of invasive candidiasis exists also in preterm neonates in neonatal intensive care unit. Diagn Microbiol Infect Dis, (56), 459-460. (Pubitemid 44854363)
47. Manzoni, P., Farina, D., Galletto, P., Leonessa, M., Priolo, C., Arisio, R., & Gomirato, G. (2007a). Type and number of sites colonized by fungi and risk of progression to invasive fungal infection in preterm neonates in neonatal intensive care unit. J Perinat Med, (35), 220-226. (Pubitemid 46700985)
48. Manzoni, P., Farina, D., Leonessa, M., d'Oulx, E.A., Galletto, P., Mostert, M., Miniero, R., &, Gomirato, G. (2006c). Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics, (118), 2359-2364. (Pubitemid 46397574)
49. Manzoni, P., Leonessa,M., Galletto, P., Latino, M.A., Arisio, R.,Maule,M., Agriesti, G., Gastaldo, L., Gallo, E., Mostert, E., & Farina, D. (2008). Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J, (27), 731-737.
50. Manzoni, P., Mostert, M., Leonessa, M.L., Priolo, C., Farina, D., Monetti, C., Latino, M.A., & Gomirato., G. (2006d). Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis, (42), 1735-1742. (Pubitemid 43839439)
51. Manzoni, P., Stolfi, I., Pugni, L., Decembrino, L., Magnani, C., Vetrano, G., Tridapalli, E., Corona, G., Giovannozzi, C., Farina, D., Arisio, R., Merletti, F., Maule, M., Mosca, F., Pedicino, R., Stronati, M., Mostert, M., & Gomirato, G. (2007b). A multi-center, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med, (356), 2483-2495. (Pubitemid 46919774)
52. Marr, K.A., Seidel, K., Slavin, M.A., Bowden, R.A., Schoch, H.G., Flowers, M.E., Corey, L., & Boeckh, M. (2000b). Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term followup of a randomized, placebo-controlled trial. Blood, (96), 2055-2061.
53. Marr, K.A., Seidel, K., White, T.C., & Bowden, R.A. (2000a). Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis, (181), 309-316. (Pubitemid 30049062)
54. Ozturk, M.A., Gunes, T., Koklu, E., Cetin, N., & Koc, N. (2006). Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses, (49), 484-492. (Pubitemid 44511100)
55. O'Grady, M.J. & Dempsey, E.M. (2008). Antifungal prophylaxis for the prevention of neonatal candidiasis? Acta Paediatr, (97), 430-433. (Pubitemid 351432307)
56. Pappas, P.G., Rex, J.H., Sobel, J.D., Filler, S.G., Dismukes, W.E., Walsh, T.J., & Edwards, J.E. (2004). Guidelines for treatment of candidiasis. Clin Infect Dis, (38), 161-189. (Pubitemid 38113025)
57. Parikh, T.B., Nanavati, R.N., Patankar, C.V., Suman Rao, P.N., Bisure, K., Udani, R.H., & Mehta, P. (2007). Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants. Indian Pediatr, (44), 830-837. (Pubitemid 350176034)
58. Candidiasis. In Pickering, L., Baker, C.J., Long, S.S., & McMillian, J.A., (Eds.) (2006). Red Book. Report of the Committee on Infectious Diseases. (27th ed.). Elk Grove Villiage, IL: American Academy of Pediatrics. pp. 246.
59. Procianoy, R.S., Eneas,M.V., & Silveira, R.C. (2006). Empiric guidelines for treatment of Candida infection in high-risk neonates. Eur J Pediatr, (165), 422-423.
60. Saiman, L., Ludington, E., Dawson, J.D., Patterson, J.E., Rangel-Frausto, S., Wiblin, R.T., Blumberg, H.M., Pfaller, M., Rinaldi, M., Edwards, J.E., Wenzel, R.P., & Jarvis, W. (2001). Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J, (20), 1119-1124. (Pubitemid 34016422)
61. Saiman, L., Ludington, E., Pfaller, M., Rangel-Frausto, S., Wiblin, R.T., Dawson, J., Blumberg, H.M., Patterson, J.E., Rinaldi, M., Edwards, J.E., Wenzel, R.P., & Jarvis, W. (2000). Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J, (19), 319-324. (Pubitemid 30213071)
62. Sarvikivi, E., Lyytikainen, O., Soll, D.R., Pujol, C., Pfaller, M.A., Richardson, M., Koukila-Kahkola, P., Luukkainen, P., & Saxen, H. (2005). Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol, (43), 2729-2735. (Pubitemid 40827946)
63. Schuman, P., Capps, L., Peng, G., Vazquez, J., el Sadr, W., Goldman, A.I., Alston, B., Besch, C.L., Vaughn, A., Thompson, M.A., Cobb, M.N., Kerkering, T., & Sobel, J.D. (1997). Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med, (126), 689-696. (Pubitemid 27184039)
64. Sims, M.E., Yoo, Y., You, H., Salminen, C., & Walther, F.J. (1988). Prophylactic oral nystatin and fungal infections in very-low- birthweight infants. Am J Perinatol, (5), 33-36. (Pubitemid 18046526)
65. Smith, P.B., Morgan, J., Benjamin, J.D., Fridkin, S.K., Sanza, L.T., Harrison, L.H., Sofair, A.N., Huie-White, S., & Benjamin, D.K., Jr. (2007). Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J, (26), 197-200. (Pubitemid 46340764)
66. Sobel, J.D., Wiesenfeld, H.C., Martens, M., Danna, P., Hooton, T.M., Rompalo, A., Sperling, M., Livengood, C., III, Horowitz, B., Von Thron, J., Edwards, L., Panzer, H., & Chu, T.C. (2004). Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med, (351), 876-883.
67. Stoll, B.J., Hansen, N.I., Adams-Chapman, I., Fanaroff, A.A., Hintz, S.R., Vohr, B., & Higgins, R.D. (2004). Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA, (292), 2357-2365. (Pubitemid 39491920)
68. Stoll, B.J., Hansen, N., Fanaroff, A.A., Wright, L.L., Carlo, W.A., Ehrenkranz, R.A., Lemons, J.A., Donovan, E.F., Stark, A.R., Tyson, J.E., Oh, W., Bauer, C.R., Korones, S.B., Shankaran, S., Laptook, A.R., Stevenson, D.K., Papile, L.A., & Poole, W.K. (2002). Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics, (110), 285-291. (Pubitemid 34833012)
69. Stoll, B.J., Temprosa, M., Tyson, J.E., Papile, L.A., Wright, L.L., Bauer, C.R., Donovan, E.F., Korones, S.B., Lemons, J.A., Fanaroff, A.A., Stevenson, D.K., Oh, W., Ehrenkranz, R.A., Shankaran, S., & Verter, J. (1999). Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics, (104), e63.
70. Uko, S., Soghier, L.M., Vega, M., Marsh, J., Reinersman, G.T., Herring, L., Dave, V.A., Nafday, S., & Brion, L.P. (2006). Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics, (117), 1243-1252. (Pubitemid 46071518)
71. Vaden, S.L., Heit, M.C., Hawkins, E.C., Manaugh, C., & Riviere, J.E. (1997). Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid. J Vet Pharmacol Ther, (20), 181-186. (Pubitemid 27244740)
72. Walsh, T.J., Gonzalez, C.E., Piscitelli, S., Bacher, J.D., Peter, J., Torres, R., Shetti, D., Katsov, V., Kligys, K., & Lyman, C.A. (2000). Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J Clin Microbiol, (38), 2369-2373. (Pubitemid 30414367)
73. Weitkamp, J.H., Ozdas, A., Lafleur, B., & Potts, A.L. (2008). Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol, (286), 405-411. (Pubitemid 351780934)
74. Weitkamp, J.H., Poets, C.F., Sievers, R., Musswessels, E., Groneck, P., Thomas, P., & Bartmann, P. (1998). Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection, (26), 11-15. (Pubitemid 28062153)
75. White, T.C., Marr, K.A., & Bowden, R.A. (1998). Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev, (11), 382-402. (Pubitemid 28197359)
76. Yoder, B.A., Sutton, D.A.,Winter, V., & Coalson, J.J. (2004). Resistant Candida parapsilosis associated with long term fluconazole prophylaxis in an animal model. Pediatr Infect Dis J, (23), 687-688. (Pubitemid 38924902)
77. Zaoutis, T.E., Heydon, K., Localio, R., Walsh, T.J., & Feudtner, C. (2007). Outcomes attributable to neonatal candidiasis. Clin Infect Dis, (44), 1187-1193. (Pubitemid 46651243)